The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.

Clinical research by Zepbound's manufacturer Eli Lilley found that the drug's active ingredient tirzepatide reduces sleep apnea by about 60%.

Lisa Jarvis In a new study, an experimental obesity drug from Novo Nordisk called CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish ...

The president-elect made the announcement on Truth Social on Sunday. ABC News’ MaryAlice Parks discusses President Joe Biden's invitation for President-elect Donald Trump to visit the White ...

The City of Athens will welcome the New Year 2025 with an innovative music and theatre spectacle which will be entirely accessible.